Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Aim

To compare changes in gut microbiota of IBS patients and healthy controls using next generation sequencing method like Illumina sequencing based on 16S rDNA profiling.

The major objectives of the study are:

To characterize type of bacterial species and compare diversity of the host's gut microbiota in 20 Irritable bowel syndrome (IBS) patients with 16 healthy controls (HCs) using high through put culture-independent method like Illumina sequencing.

To study modulation of gut microbiota profile after treatment with probiotics (VSL #3) for 8 weeks.

To study the improvement of symptoms after modulation of gut microbiota with probiotics (VSL #3) for more than 8 weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asian Institute of Gastroenterology, India

Criteria

Inclusion Criteria:

• Patients satisfying Rome III Criteria

Exclusion Criteria:

• Antimicrobial medication during last 2 months

• Probiotics medication during last 2 months

• Pregnant or lactating patients

• Previous major or complicated abdominal surgery

• Positive test for HIV, HBV or HCV